New IMC report shows impact of chronic disease and increased claims on private drug plans

January 13, 2021

Growth in chronic disease and increased drug claims […]

Delaying implementation of PMPRB’s Regulations an opportunity to protect patient access to medicines and vaccines

December 30, 2020

We support Health Canada’s decision to delay […]

IMC says there is still time for the federal government to put Canadian patients first by delaying the January 1, 2021 implementation of PMPRB’s Regulations and Guidelines

December 29, 2020

Ottawa, December 29, 2020 – Innovative Medicines Canada (IMC) issued the following statement today regarding the looming implementation of the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines, […]

Still time for federal government to act to protect patient access to new medicines and vaccines before January 1, 2021 implementation of new PMPRB Regulations and Guidelines

December 21, 2020

Ottawa, December 21, 2020—Innovative Medicines Canada (IMC) issued the following statement today warning of the impact the Patented Medicines Prices Review Board’s (PMPRB’s) Final Regulations and Guidelines will have on […]

IMC asks country’s First Ministers to show support for Canadian patients in December 10 meeting with Prime Minister Trudeau

December 9, 2020

Ottawa, December 9, 2020 – Innovative Medicines Canada (IMC) issued the following statement today regarding its recent letter to Canada’s First Ministers in advance of their meeting this Thursday with […]

Statement: IMC responds to Health Canada’s Interim Order Respecting Drug Shortages

December 2, 2020

Ottawa, December 2, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Interim Order Respecting […]

Statement: COVID-19 Vaccine Manufacturing Capacity

November 25, 2020

IMC issued the following statement today in response to questions […]

Innovative Medicines Canada Statement Regarding the Potential Disclosure of Proprietary or Commercially-Sensitive Business Information

October 26, 2020

Ottawa, October 23, 2020—Innovative Medicines Canada (IMC) issued the following statement in response to the potential disclosure of proprietary or confidential business information regarding the procurement of COVID-19 medicines and […]

Innovative Medicines Canada responds to the Trump administration’s plan to allow the importation of prescription drugs from Canada

September 28, 2020

STATEMENT Ottawa, September 25, 2020 – The following statement can be attributed to Declan Hamill, Vice President, Legal, Regulatory Affairs & Compliance, Innovative Medicines Canada in response to the Trump […]

Innovative Medicines Canada responds to today’s Speech from the Throne

September 23, 2020

STATEMENT Ottawa, September 23, 2020 – Pamela Fralick, President of Innovative Medicines Canada, issued the following statement in response to today’s Speech from the Throne: “COVID-19 has shown just how […]